CVS to carry cannabis producer Curaleaf CBD products

携带大麻生产商 Curaleaf CBD 产品的CVS

2019-03-21 06:18:00 MarketWatch


By U.S. cannabis retailer Curaleaf Holdings Inc. said late Wednesday that it has inked a deal with CVS Health Corp. to carry its line of cannabidiol, or CBD, products. Curaleaf CURLF, +3.44%  does not trade after hours and CVS CVS, -1.63%  was down less than 0.1% in extended trading after the announcement. Executives on Curaleaf’s earnings conference call said CVS would begin to carry its Curaleaf Hemp lotions and trans-dermal patches — which include items with CBD — in 800 stores across 10 states in the U.S. Chief Executive Joe Lusardi said in the call that the products would be available by Friday through the CVS website. The U.S. Food and Drug Administration has said that CBD remains a drug ingredient and as a result is illegal to add to food and health products. A company spokeswoman could not immediately respond to questions MarketWatch had about the FDA’s position and Curaleaf’s product line that will soon be sold at CVS. Curaleaf on Wednesday reported widening net losses, while growing revenue more than 400%. The company reported fourth-quarter net losses of $16.5 million, or 4 cents a share, compared with profits of $624,000, or zero cents a share in the year-ago quarter. Revenue rose to $32 million from $6.3 million in the year-ago period, excluding revenue from managed entities. There are not enough analysts polled by FactSet on Curaleaf earnings or revenue to form reliable consensus estimates. Curaleaf said insiders and investors agreed to voluntarily lock up their shares until April 29, representing roughly 3% of shares and about an additional 80% of outstanding shares will voluntarily be locked up until Oct. 20. The company reiterated its full-year revenue guidance of $400 million. Curaleaf stock has gained 50% in the past three months, as the S&P 500 index SPX, -0.29%   has risen 15%. Max A. Cherney is a MarketWatch reporter based in San Francisco. Follow him on Twitter @chernandburn.
由。 美国大麻零售商 Curaleaf Holdings Inc .周三晚间说,该公司已与 CVS Health Corp .签署协议,将经营其大麻产品线。 Curaleaf CURLF ,+3.44% 小时后不进行交易, CVS CVS ,-1.63% 该公告发布后,在扩大交易中下跌不到0.1%。 Curaleaf 盈利电话会议的高管们表示, CVS 将开始在美国10个州的800家门店销售其 Curaleaf Hemp 洗剂和透皮贴剂(包括 CBD 产品),首席执行长卢扎迪( Joe Lusardi )在电话会议上说,这些产品将在周五通过 CVS 网站提供。 美国食品药品监督管理局(Food and Drug Administration)表示, CBD 仍然是一种药物成分,因此添加到食品和保健品中是非法的。 一位公司发言人无法立即回答 MarketWatch 对 FDA 的立场和 Curaleaf 很快将在 CVS 上销售的产品线的问题。 Curaleaf 周三公布,其净亏损扩大,营收增长逾400%. 该公司公布第四季度净亏损1650万美元,合每股4美分,上年同期利润为62.4万美元,合每股0美分。收入从一年前的630万美元增加到3200万美元,其中不包括管理实体的收入。 FactSet 对 Curaleaf 的收益或收入进行了调查,但没有足够多的分析师得出可靠的共识估计。 Curaleaf 说,内部人士和投资者同意自愿锁定他们的股票,直到4月29日,约3%的股份和约80%的流通股将自愿锁定到10月20日。 该公司重申其全年收入目标为4亿美元。 在过去的三个月里, Curaleaf 股票上涨了50%,作为标准普尔500指数 SPX ,-0.29% 上涨了15%。 Max A.Cherney 是一位驻旧金山的市场观察记者,在 Twitter @ chernandburn 上关注他。